Contribution: Industrial Research Assistance Program – Contributions to Firms
Ripple Therapeutics Corp.
$810,564.00
IBE-814 IVT Diabetic Macular Edema and Retinal Vein Occlusion
FY 2021-22 · 2022-01-01
Summary
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. Scientific and engineering resources will perform work on the development of Ripple’s lead product IBE-814 IVT for the treatment of Diabetic Macular Edema and Retinal Vein Occlusion. The project will require analysis of data generated from the ongoing clinical trial, and development and scale up of the product for the next stages on the path to commercialization.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
760459073
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2022-01-01 | 2021-22 | $500,000.00 |
| 1 | 2022-01-01 | 2021-22 | $750,000.00 |
| 2 | 2022-01-01 | 2021-22 | $810,564.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by -120 days. The total amended value is 60,564 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de -120 jours. La valeur totale des modifications est de 60 564 dollars.
Agreement End Date
2023-01-31
Agreement Number
986775
Agreement Start Date
2022-01-01
Agreement Title
IBE-814 IVT Diabetic Macular Edema and Retinal Vein Occlusion
Agreement Title (French)
IBE-814 IVT – Œdème maculaire diabétique et occlusion veineuse rétinienne
Agreement Type
Contribution
Agreement Value
$810,564.00
Amendment Date
2023-03-01
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. Scientific and engineering resources will perform work on the development of Ripple’s lead product IBE-814 IVT for the treatment of Diabetic Macular Edema and Retinal Vein Occlusion. The project will require analysis of data generated from the ongoing clinical trial, and development and scale up of the product for the next stages on the path to commercialization.
Description (French)
Ripple Therapeutics Corporation est une société privée en phase clinique qui se concentre sur les thérapies ophtalmiques avec administration de médicaments contrôlable et durable. Les ressources scientifiques et d'ingénierie travailleront à la mise au point du produit phare de Ripple, IBE-814 IVT, pour le traitement de l'œdème maculaire diabétique et de l'occlusion veineuse rétinienne. Le projet nécessitera l'analyse des données générées par l'essai clinique en cours, ainsi que la mise au point et la mise à l'échelle du produit pour les prochaines étapes du processus jusqu'à sa commercialisation.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
32541
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
760459073
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Ripple Therapeutics Corp.
Recipient Operating Name
Ripple Therapeutics
Recipient Postal Code
M5G 1L7
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2021-2022-Q4-986775
